Stockreport

Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

Selecta Biosciences, Inc.  (SELB) 
Last selecta biosciences, inc. earnings: 3/12 08:00 am Check Earnings Report
PDF – Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Pha [Read more]